Latest Cost Management News

Temple & Webster Group has reported a record FY25 revenue of $601 million, marking a 21% increase year-on-year, alongside a 43% rise in EBITDA. The company is confidently progressing towards its ambitious $1 billion mid-term revenue target.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

Comms Group reported robust FY25 results driven by domestic expansion, including the strategic acquisition of TasmaNet, and strong international growth in its Global and Wholesale division.

Web Travel Group Limited has reported a robust first half of FY26 with a 22% increase in Total Transaction Value and EBITDA growth surpassing expectations, setting a confident tone for the year ahead.

Metroglass has reported a 5% revenue decline in its half-year results but achieved a significant reduction in net debt and improved profitability, signaling progress in its turnaround strategy amid challenging market conditions.

Integrated Research Limited reported a modest revenue dip and significant profit declines in FY25 as it pivots to a product-led growth strategy focused on AI-powered observability solutions and hybrid pricing models.

Adore Beauty Group has reported record profitability for FY25, driven by improved revenue quality, operational efficiencies, and rapid retail expansion. The company’s omni-channel strategy is gaining momentum with strong customer growth and a new fulfillment center planned for FY27.

Elevra Lithium reports a 31% surge in spodumene concentrate production for FY25, alongside significant resource expansions and a clear growth roadmap post-merger.

Sims Limited reports a stellar FY25 with underlying EBIT nearly tripling, driven by strategic growth and sustainability achievements, while setting an ambitious outlook for FY26 amid market challenges.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Oceania Healthcare reported a slight dip in revenue but impressive gains in profitability for the first half of 2025, highlighting operational resilience amid a challenging environment.